BioPharma Dive
What it covers
Latest stories it covered
FDA declines approval of Summit Therapeutics’ ivonescimab for non-small cell lung cancer
The US Food and Drug Administration (FDA) declines to approve Summit Therapeutics’ investigational bispecific antibody ivonescimab for a non-small cell lung cancer (NSCLC) indicati...
Eli Lilly to buy Calytrix Bio for up to $1.5 billion
Eli Lilly is set to acquire Calytrix Bio in a deal worth up to $1.5 billion. Calytrix is a privately held biotechnology company backed by JPMorgan Chase, and it is developing thera...
Johnson & Johnson agrees to buy Ollin Biosciences for about $2.2bn
Johnson & Johnson has agreed to acquire Ollin Biosciences, a clinical-stage biotech focused on therapies for serious eye diseases. Quartz and the Wall Street Journal Tech both repo...
Blackstone to fund Pfizer’s monthly berobenatide Phase 3 obesity drug studies
Pfizer is securing as much as $1.5 billion from Blackstone to support development of its monthly obesity drug berobenatide, according to multiple outlets. The funding is tied to ad...
PepGen reports promising early trial results for muscular dystrophy drug
PepGen says early data from a small study of its muscular dystrophy treatment look promising. Across the limited trial findings, the company reports that its therapy is showing sig...
FDA approves Bayer’s Sunharbo, a first-in-class Factor XIa stroke blood thinner
Bayer’s Sunharbo receives U.S. FDA approval as a once-daily blood thinner intended to reduce the risk of an additional stroke. Quartz reports the approval is based on trial results...
Argenx agrees to acquire Unnatural Products for development of macrocyclic peptide medicines
Argenx has agreed to acquire Unnatural Products, a biotechnology firm working on a macrocyclic peptide platform. One report says the deal would give Argenx control of the technolog...
FDA investigates possible tumor risk in children treated with Novartis’ Zolgensma gene therapy
The US Food and Drug Administration is investigating reports of tumors, including malignancies, in children who received Novartis’ one-time gene therapy Zolgensma for spinal muscul...
Hims and Lilly agree on GLP-1 partnership amid Hims shift in drug practices
Hims and Hers reaches a deal with Lilly covering GLP-1 medicines, and Hims’ stock rises following the announcement. Under the agreement, Hims says it will stop future compounding o...
CVS Health plans to split into two publicly traded companies separating pharmacies from insurance
CVS Health announces plans to break up its business into two separate publicly traded companies, separating retail pharmacy operations from its insurance and prescription-benefit u...
CMS finalizes 2027 outpatient payment rule cutting 340B drug payments and expanding site-neutral payments
Regulators finalize a CMS rule that changes Medicare payments starting in 2027, including major reductions for drugs covered under the 340B program and expanded “site-neutral” paym...
Revolution Medicines’ Rasonque sees strong early sales as analysts reassess launch expectations
Revolution Medicines’ new pancreatic cancer drug, Rasonque, is getting a strong early commercial response, prompting Wall Street analysts to reassess projections. Across outlets, c...
Novo Nordisk raises 2026 forecast as Wegovy pill sales top expectations
Novo Nordisk raises its 2026 outlook again after third-quarter results show stronger-than-expected demand for its Wegovy weight-loss pill. Multiple outlets say the company increase...
KFF projects 50% average rise in Medicare Part D premiums in 2027
Medicare Part D premiums are projected to increase sharply in 2027, with KFF analysis indicating an average rise of about 50%. News coverage highlights that the average monthly pre...
DOL finalizes PBM disclosure rule requiring fee and compensation transparency for employers
The U.S. Department of Labor finalizes a rule aimed at increasing transparency in how pharmacy benefit managers (PBMs) are paid. Multiple outlets report the final requirements focu...
HHS temporarily allows compounding pharmacies to make six unapproved peptides
The U.S. Department of Health and Human Services (HHS) announces a policy that temporarily allows 503A compounding pharmacies to produce six specific peptides through patient-speci...
Lilly’s retatrutide outperforms Ozempic in trial on weight loss and blood sugar control
Eli Lilly reports that its experimental obesity and diabetes drug retatrutide, often described as a “triple-G” medicine, performs better than Novo Nordisk’s Ozempic in a head-to-he...
Artiva to shut down autoimmune cell therapy program after patient deaths
Artiva is winding down its autoimmune cell therapy work after two deaths reported in a trial of the approach, according to STAT+. The company says the recent fatalities are a setba...
Judge rejects Novo Nordisk bid to halt Eli Lilly weight-loss drug ads
A federal judge rejects Novo Nordisk’s request to block Eli Lilly from running advertising for its weight-loss drug(s), ruling that Novo did not show it would suffer meaningful, ir...
Moderna and Merck cancer vaccine data leak sparks market selloff despite promising melanoma results
Moderna and Merck shares fall after partial clinical data for the personalised mRNA cancer vaccine with Merck leaks ahead of schedule, prompting investor concerns before the full r...